搜索
Search
img
苏州开拓药业股份有限公司
专注于大量未被满足临床需求的疾病领域
PREV
NEXT
苏州开拓药业股份有限公司
苏州开拓药业股份有限公司

About Us

We concentrate on cancers and other high-incidence diseases to fulfill numerous unmet medical needs. Our particular expertise is in Androgen Receptor related diseases

Including prostate cancer, breast cancer, liver cancer, alopecia and other diseases that not only affect a large number of patients but also lack effective treatments

Our diverse product pipeline is built on a foundation of internal R&D and supplemented with external licensing. We are committed to provide the best therapeutics for our patients

这是描述信息
这是描述信息

Small-molecule innovative drugs

The product pipeline primarily focuses on AR antagonists and was subsequently expanded to include mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents and cMyc inhibitors.

这是描述信息

Innovative biologics

Our first novel biologic drug, an ALK-1 antibody licensed from Pfizer, is expected to become a "first-in-class" biologic for multiple cancers. From this project , Kintor biologics start to layout in the biologics area.

这是描述信息

Combination therapy

In order to provide the best treatment plan for prostate cancer, breast cancer, liver cancer and other deseases, we are creating diverse combination therapies with our own innovative drugs at core.

Our Platform

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

 In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

R&D Platform

 We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

 In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2020-08-04

Results of Kintor's Phase Ib Clinical Trials of Pyrilutamide in America

Kintor Pharmaceutical Limited (stock code: 9939.HK, hereinafter referred to as "Kintor" or the "Company") announced that the phase Ib clinical trials of Pyrilutamide (KX-826) against androgenetic alopecia were completed in the United States. All subjects exited the trials. Data analysis, cleaning and summarisation are underway.

2020-07-30

Kintor Pharmaceutical and Alphamab Oncology Announce Partnership to Develop Combination Therapy of GT90001 and KN046

Kintor Pharmaceutical Limited (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced that the Company has entered a partnership agreement with Alphamab Oncology (stock code: 9966.HK), to jointly develop the combination therapy of ALK-1 monoclonal antibody GT90001 and PD-L1 / CTLA-4 bispecific antibody KN046 in hepatocellular carcinoma (HCC).

2020-07-19

Kintor Pharmaceutical's Proxalutamide Completes Patients Enrolment for Phase II Clinical Trials in the US

Kintor Pharmaceutical Limited (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced the completion of patients enrolment according to the clinical protocol for phase II clinical trials (NCT03899467) of Proxalutamide (GT0918) in the United States for treating metastatic castration-resistant prostate cancer (“mCRPC”).

Talent Recuritment

这是描述信息
这是描述信息